← Eichor
Study identifier: NCT07408531 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

Condition: Lung Cancer Screening  ·  Sponsor: University of Illinois at Chicago

PhaseNA
Planned participants2500
Who can joinAll sexes, 50 Years to 80 Years
Healthy volunteersYes

About this study

This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.

This description comes directly from the study's public registry record.

Talk to the study team

Mary Pasquinelli, DNP  ·  (312) 996-8039  ·  Mpasqu3@uic.edu

Always discuss trial participation with your own doctor first.

Locations (2)

University of Illinois Cancer CenterChicago, Illinois, United StatesRecruiting
UI Health 55th and Pulaski Health CollaborativeChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07408531